Serum Clusterin: A Potential Marker for Assessing the Clinical Severity and Short-Term Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure

Table 2

Association between serum clusterin level and clinical parameters in patients with hepatitis B virus-related acute-on-chronic liver failure.

Patient’s parameters	Number of cases	Clusterin (μg/mL)	value
Age (years)			0.608
≤55	90
>55	18
Gender			0.075
Female	23
Male	85
Pathological base			0.489
Chronic hepatitis	72
Liver cirrhosis	36
Infection			0.478
With	31
Without	77
HBV DNA (log10 IU/mL)			0.388
≤10	41
>10	67
Serum creatinine (mg/dL)			0.566
≤1.50	99	51.09 (12.17, 231.86)
>1.50	9	65.67 (20.36, 188.62)
TBIL (mg/dL)			0.518
5-10 mg/dL	20
10-15 mg/dL	34
≥15 mg/dL	54
HBV-ACLF stages			<0.001
	44
	44
	20
90-day outcome			<0.001
Survival	74
Nonsurvival	34
Survival time of the deaths (days)			0.013
≤28	21	28.39 (12.62, 68.96)
>28	13	43.22 (28.01, 69.96)

Data are presented as (%), , or median (minimum, maximum). Abbreviations: HBV DNA: hepatitis B virus DNA; PTA: prothrombin activity; HBV-ACLF: hepatitis B virus-related acute-on-chronic liver failure. Comparison among groups by one-way ANOVA. values in bold numerals indicate significant values.